We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Official: Agency May Need Accelerated Withdrawal Process
FDA Official: Agency May Need Accelerated Withdrawal Process
December 16, 2011
The FDA should consider a speedier way to withdraw indications granted under accelerated approval in light of the recent resource-intensive, time-consuming effort to revoke the metastatic breast cancer (MBC) indication for Genentech’s Avastin, CBER Director Karen Midthun says.